265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Caspian Oliai, MD, MS; Rasmus T Hoeg, MD; Anna Pavlova, MD, PhD; Arpita Gandhi, MD; Lori Muffly, MD; Rohtesh S. Mehta, MD; Samer A Sour, MD, MS; Edmund K. Waller, MD, PhD; Robert Lowsky, MD; Sagar S. Patel, MD; Bhagirathbhai Dholaria, MBBS; Carlos Bachier, MD; Jeremy M. Pantin, MD, FACP; Amandeep Salhotra, MD; Joseph P. McQuirk, DO; Nathaniel B Fernhoff, PhD; J Scott McClellan, MD; Mehrdad Abedi, MD; Robert S. Negrin, MD; and Everett H Meyer, MD, PhD

https://ash.confex.com/ash/2022/webprogram/Paper165654.html

640 Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA

Hitomi Hosoya, MD, PhD; Mia Carleton; Kailee L Tanaka; Brian Sworder, MD, PhD; Vanna Hovanky; George E Duran, BA; Tian Y. Zhang, MD, PhD; Michael S. Khodadoust, MD PhD; David B. Miklos, MD; PhD; Sally Arai, MD; David Iberri, MD; Michaela Liedtke, MD; Surbhi Sidana, MD; and David M. Kurtz, MD, PhD

https://ash.confex.com/ash/2022/webprogram/Paper160370.html

982 CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study

Nikeshan Jeyakumar, MD; Sneha Ramakrishna, MD; Matthew J Frank, MD, PhD; Bita Sahaf, PhD; Steven A. Feldman, PhD; David B. Miklos, MD, PhD; Crystal L. Mackall, MD; Kara L. Davis, D.O.; Lori Muffly, MD, MS; and Liora M. Schultz, MD

https://ash.confex.com/ash/2022/webprogram/Paper164456.html

543 Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Brian Sworder, MD, PhD; David M. Kurtz, MD, PhD; Stefan K. Alig, MD; Matthew J Frank, MD, PhD; Navika D. Shukla, MD; Andrea Garofalo; Charles Macaulay, MSc, BA; Mohammad Shahrrok Esfahani, PhD; and
720 Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Emily C. Liang, MD; Simone E. Dekker, MD, PhD; Jean M.G. Sabile, MD; Stefan Torelli, MD; Amy Zhang, MPH; Katharine Miller, PhD; Parveen Shiraz, MD; Brandon Hayes-Lattin, MD; Jessica Leonard, MD; and Lori Muffly, MD

994 Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Lori Muffly, MD, MS; Ariadna Garcia; Katharine Miller, PhD; Theresa H.M. Keegan, PhD; and Helen Parsons, PhD MPH

110 Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals

Lu Cui, Cristabelle De Souza, Ph.D.; Tristan Lerbs; Jessica Poyser; Clarissa Yu; Kerri Rieger, MD PhD; Sally Arai, MD; Ryanne Brown; Judith A Shizuru, MD, PhD; Antonia Maria Susanne Müller; and Gerlinde Wernig, MD

https://ash.confex.com/ash/2022/webprogram/Paper165545.html

https://ash.confex.com/ash/2022/webprogram/Paper157442.html

https://ash.confex.com/ash/2022/webprogram/Paper163840.html

https://ash.confex.com/ash/2022/webprogram/Paper169789.html

https://ash.confex.com/ash/2022/webprogram/Paper169789.html
765 Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Matthew A. Lunning, DO, FACP1, Hai-Lin Wang, MPH2*, Zhen-Huan Hu, MPH2, Frederick L. Locke, MD3, Tanya Siddiqi, MD4, Caron A. Jacobson, MD4, Sairah Ahmed, MD5, David B. Miklos, MD, PhD6, Yi Lin, MD, PhD6, Brian T. Hill, MD, PhD6, Armin Ghobadi, MD7, Sattva S. Neelapu, MD8, Jason Westin, MD9, Harry Miao, MD, PhD10, Shilpa Shahani, MD11, Anik R. Patel, PhD12, Clare Spooner, MBBS, BSc13, Christine Fu, PhD14, Hairong Xu, MD, PhD14 and Marcelo C Pasquini, MD, MS15

659 Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, MD1, Javier Munoz, MD, MS, MBA2, Jason Westin, MD3, Frederick L. Locke, MD4, David B. Miklos, MD, PhD5, Aaron P. Rapoport, MD6, Miguel-Angel Perales, MD7, Patrick M. Reagan, MD8, Joseph P. McGuirk, DO9, Caron A. Jacobson, MD10, Marie José Kersten, MD, PhD11, Irit Avivi, MD12, Andrew Peng, MS13, Marco Schupp, MD14, Christina To, MD15 and Olalekan O. Oluwole, MBBS16

766 Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Christopher J. Ferreri, MD1, Michelle A.T. Hildebrandt, PhD1, Hamza Hashmi, MD2, Leyla O. Shune, MD3, Joseph P. McGuirk, DO4, Douglas W. Sborov, MD5, Charlotte B Wagner, PharmD6, M. Hakan Kocoglu, MD7, Shebli Atrash, MD8, Peter M. Voorhees, MD9, Jack Khouri, MD10, Danai Dima, MD11, Aimaz Afrough, MD12, Aishwarya Sannareddy, MBBS13, Gary Simmons, DO14, James Davis, PharmD15, Nilesh Kalariya16, Lauren C. Peres, PhD, MPH17, Melissa Alsina, MD18, Frederick L. Locke, MD19, Surbhi Sidana, MD17, Doris K. Hansen, MD20, Krina Patel, MD, MSc21 and Omar Alexis Castaneda Puglianini, MD22

252 Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

https://ash.confex.com/ash/2022/webprogram/Paper158303.html

https://ash.confex.com/ash/2022/webprogram/Paper164884.html

https://ash.confex.com/ash/2022/webprogram/Paper168303.html
Lauren C. Peres, PhD, MPH1*, Laura B. Oswald, PhD2*, Christen Dillard, MD3, Gabriel De Avila, BS4, Taiga Nishihori, MD5, Brandon J. Blue, MD3, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP4, Frederick L. Locke, MD6, Melissa Alsina, MD**8, Omar Alexis Castaneda Pugliani, MD9, Leyla O. Shune, MD10, Douglas W. Sborov, MD11, Charlotte B Wagner, PharmD12, Danai Dima, MD11, Hamza Hashmi, MD14, James Davis, PharmD15, M. Hakan Kocoglu, MD16, Shebli Atrash, MD17, Gary Simmons, DO18, Niles Kalariya19, Christopher J. Ferreri, MD20, Aishwarya Sannareddy, MBBS1*, Surbhi Sidana, MD21, Doris K. Hansen, MD22 and Krina Patel, MD, MSc23

https://ash.confex.com/ash/2022/webprogram/Paper158478.html

476 Microbial Bile Acid Metabolism Shapes Effector T Cell Responses during Inflammation in Mouse and Human

Sarah Lindner, MD1*, Oriana Miltiadous, MD2*, Ruben J Ramos3, Anqi Dai, MS4, Anastasia Kousa, PhD5, Gabriel K Armijo6, Romina Ghale7, Chi L Nguyen8, Jenny Paredes Sanchez, PhD9, Teng Fei, PhD10, John W Frame V11, Sebastien Monette, DMV, MVSc12, Emily Fontana13, John Slingerland14, Ying Taur, MD, MHP15, Marina D Burgos da Silva, PhD16, Kate A Markey, MBBS, M Clin Res, PhD, FRACP17, Jonathan U Peled, MD, PhD18, Melody Smith, MD, MS19, Sergio A Giralt, MD20, Miguel-Angel Perales, MD21, Justin R Cross, PhD22, Clarissa Campbell, PhD23 and Marcel R M van den Brink, MD, PhD24

https://ash.confex.com/ash/2022/webprogram/Paper167809.html

769 Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Amandeep Salhotra, MD1, Samer A Srour, MD, MS2, Rasmus T Hoeg, MD3, Ayman Saad, MB/BCH4, Everett H Meyer, MD, PhD5, Anna Pavlova, MD, PhD6, Edmund K. Waller, MD, PhD7, Mwe Mwe Chao, MD8, J Scott McClellan, MD, PhD9, Nathaniel B Fernhoff, PhD10, Robert Lowsky, MD11 and Mehrdad Abedi, MD12

https://ash.confex.com/ash/2022/webprogram/Paper170459.html

Stanford BMT-CT ASH Abstracts 2022: Poster Abstracts

4657 Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Sushma Bharadwaj, MD, MS1, Mark P Hamilton, MD2, Bita Sahaf, PhD3, John Tamaresis, PhD4, Sunita Patil5, Paul J Hanson, PhD6, Theresa Latchford, RN7, Sally Arai, MD8, Laura J. Johnston, MD9, Robert

https://ash.confex.com/ash/2022/webprogram/Paper158478.html
4659 Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Surbhi Sidana, MD1, Lauren C. Peres, PhD, MPH2, Hamza Hashmi, MD, PhD3, Christopher J. Ferreri, MD4, Shebli Atrash, MD5, Jack Khouri, MD5, Peter M. Voorhees, MD6, Danai Dima, MD6, Gary Simmons, DO7, Niles Kalariya8, Vanna Hovanky9, Sushma Bharadwaj, MD, MS10, Sally Arai, MD10, David B. Miklos, MD, PhD11, Charlotte B Wagner, PharmD12, James Davis, PharmD13, Douglas W. Sborov, MD14, Taiga Nishihori, MD15, Melissa Alsina, MD16, Frederick L. Locke, MD17, Rebecca Gonzalez, PharmD, BCOP18, M. Hakan Kocoglu, MD19, Aishwarya Sannareddy, MBBS20, Aimaz Afrrough, MD21, Joseph P. McGuirk, DO22, Leyla O. Shune, MD23, Krina Patel, MD, MSc24 and Doris K. Hansen, MD25

https://ash.confex.com/ash/2022/webprogram/Paper166058.html

2106 Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

Shona Philip, MD1, Robert Lowsky, MD1, Laura J. Johnston, MD1, Sally Arai, MD2, Everett H Meyer, MD, PhD3, Robert S. Negrin, MD1, Andrew R. Rezvani, MD1, Parveen Shiraz, MD1, Judith A Shizuru, MD, PhD1, Surbhi Sidana, MD1, Wen-Kai Weng, MD, PhD6, Sushma Bharadwaj, MD, MS10, Matthew J Frank, MD, PhD1, David B. Miklos, MD, PhD1 and Vaibhav Agrawal, MD9

https://ash.confex.com/ash/2022/webprogram/Paper168546.html

2090 Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

Michelle Chin, MS1, Judith A Shizuru, MD, PhD1, Lori Muffy, MD1, Parveen Shiraz, MD1, Laura J. Johnston, MD1, Robert Lowsky, MD1, Andrew R. Rezvani, MD1, Matthew J Frank, MD, PhD1, Sushma Bharadwaj, MD, MS10, Wen-Kai Weng, MD, PhD6, Robert S. Negrin, MD1, David B. Miklos, MD, PhD1 and Sally Arai, MD1

https://ash.confex.com/ash/2022/webprogram/Paper165547.html
3358 Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Mark P Hamilton, MD1,2,3, Felicia C Liu-Fei3*, Stefan K. Alig, MD4, John Tamaresis, PhD5*, Mohammad Shahrokh Esfahani, PhD6, Zinaida Good, PhD3*, Brian Sworder, MD, PhD4, Joseph Schroers-Martin, MD6, Chih Long Liu, PhD7, Freja Tang Severinsen, BSc6*, Paul J Hanson, PhD8*, Ying Lu, PhD9, Robert Lowsky, MD2, Robert S. Negrin, MD2, Everett H Meyer, MD, PhD2, Melody Smith, MD, MS1, Sushma Bharadwaj, MD, MS5*, Judith A Shizuru, MD, PhD3,11, Surbhi Sidana, MD2,3, Parveen Shiraz, MD2, Andrew R. Rezvani, MD, Laura J. Johnston, MD2, Wen-Kai Weng, MD, PhD4, Sally Arai, MD2, Lori Muffly, MD2,3, Saurabh Dahiya, MD2, Maximilian Diehn, MD, PhD2, David M. Kurtz, MD, PhD8, Bita Sahaf, PhD2, Crystal L. Mackall, MD2,3,4, Matthew J Frank, MD, PhD2, David B. Miklos, MD, PhD2,3 and Ash A. Alizadeh, MD, PhD11,16

https://ash.confex.com/ash/2022/webprogram/Paper165600.html

2849 Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Navika D. Shukla, MD1*, Joseph Schroers-Martin, MD2, Karan R. Kathuria3*, Brian Sworder, MD, PhD4, Stefan K. Alig, MD1, Matthew J Frank, MD, PhD2, David B. Miklos, MD, PhD3, Steven Coutre, MD7, Maximilian Diehn, MD, PhD2, Michael S. Khodadoust, MD PhD2, Mark Roschewski, MD, David M. Kurtz, MD, PhD2 and Ash A. Alizadeh, MD, PhD11

https://ash.confex.com/ash/2022/webprogram/Paper165656.html

2018 A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies

Sattva S. Neelapu, MD1, Don A. Stevens, MD2, Mehdi Hamadani, MD1, Matthew J Frank, MD, PhD2, Houston Holmes, MD, MBA*, Aya Jacobovits, PhD4, John Hinkle, PhD9, Jackie Kennedy-Wilde, MS5*, Ori Maller, PhD5*, Bayarmagnai Weinstein, MD, PhD2, Francesco Galimi, MD, PhD1, Rose K LaI, MD4 and David B. Miklos, MD, PhD1

https://ash.confex.com/ash/2022/webprogram/Paper157400.html

3345 Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r)
Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, MD¹, Zhen-Huan Hu, MPH², Tanya Siddiqi, MD³, Caron A. Jacobson, MD⁴, Sarah Nikiforow, MD, PhD⁵, Sairah Ahmed, MD⁵, David B. Miklos, MD, PhD⁶, Yi Lin, MD, PhD⁷, Matthew A. Lunning, DO, FACP⁸, Brian T. Hill, MD, PhD⁹, Armin Ghabadi, MD¹⁰, Harry Miao, MD, PhD¹⁰, Shilpa Shahani, MD¹⁰, Clare Spooner, MBBS, BSc¹¹, Christine Fu, PhD¹², Anik R. Patel, PhD¹², Hairong Xu, MD, PhD¹² and Marcelo C Pasquini, MD, MS¹¹
https://ash.confex.com/ash/2022/webprogram/Paper155603.html

3866 Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, MD¹, Stefan K. Alig, MD², Brian Sworder, MD, PhD³, Joseph Schroers-Martin, MD⁴, Charles Macaulay, MSc, BA⁵, Alexander F. M. Craig, MD, MPhil⁶, Ulrich Duehrsen, MD⁷, Andreas Hüttmann, MD⁸, Jason Westin, MD⁹, Hua-Jay J. Cheng, MD¹⁰, David B. Miklos, MD, PhD¹¹, Matthew J Frank, MD, PhD¹², Maximilian Diehn, MD, PhD¹³,¹⁴, David M. Kurtz, MD, PhD¹⁴ and Ash A. Alizadeh, MD, PhD¹⁵
https://ash.confex.com/ash/2022/webprogram/Paper170087.html

4628 Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Liora M. Schultz, MD¹, Sneha Ramakrishna, MD², Reema Baskar, PhD³, Rebecca M Richards, MD, PhD⁴, Jennifer Moon, jmoon@stanfordchildrens.org⁵, Christina Baggott, RN, PhD⁶, Michelle Fujimoto⁷, Michael Kunicki⁸, Amy Li, a.li4@stanford.edu⁹, Sneha Jariwala¹°, Courtney Erickson¹¹, Ashley Jacobs¹², Karen Yamabe¹³, Valentin Barsan¹⁴, Robbie G. Majzner, MD¹⁵, Emily L. Egeler, PhD¹⁶, Sharon Mavroukakis¹⁷, Zachary Ehlinger, MS¹⁸, Warren D. Reynolds, BS¹⁹, Bita Sahaf, PhD²⁰, Lori Muffy, MD²¹, Matthew J Frank, MD, PhD²², Anne-Louise Gramstrup²³, Harshini Chinnsamy, MS²⁴, Shabnum Patel, PhD²⁵, David B. Miklos, MD, PhD²⁶, Steven A. Feldman, PhD²⁷, Crystal L. Mackall, MD²⁸ and Kara L. Davis, D.O.²⁹
https://ash.confex.com/ash/2022/webprogram/Paper167789.html

4199 Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
4677 Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Jack Khouri, MD1, Hong Li, MS2, Doris K. Hansen, MD3, Surbhi Sidana, MD4, Leyla O. Shune, MD5, Shaun DeJarnette6, Faiz Anwer, MD7, Douglas W Sborov8, Charlotte B Wagner, PharmD9, M. Hakan Kocoglu, MD10, Shebli Atrash, MD11, Peter M. Voorhees, MD12, Jason Valen, MD13, Lauren C. Peres, PhD, MPH14, Vanna Hovanky15, Gary Simmons, DO16, Danai Dima, MD17, Nilesh Kalariya18, Aimaz Afrough, MD19, Gurbakhsh Kaur, MD20, Aishwarya Sannareddy, MBBS21, Christopher J. Ferreri, MD22, James Davis, PharmD23, Joseph P. McGuirk, DO24, Frederick L. Locke, MD25, Rachid C. Baz, MD26, Betty K. Hamilton, MD27, Melissa Alsina, MD28, Craig S. Sauter, MD29, Hamza Hashmi, MD30 and Krina Patel, MD, MSc31

https://ash.confex.com/ash/2022/webprogram/Paper164828.html

2027 Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Hamza Hashmi, MD1, Doris K. Hansen, MD2, Lauren C. Peres, PhD, MPH3, Omar Alexis Castaneda Pugliani, MD4, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP5, Gabriel De Avila, BS6, Surbhi Sidana, MD7, Leyla O. Shune, MD8, Douglas W. Sborov, MD9, James Davis, PharmD10, Charlotte B Wagner, PharmD11, M. Hakan Kocoglu, MD12, Shebli Atrash, MD13, Peter M. Voorhees, MD14, Gary Simmons, DO15, Christopher J. Ferreri, MD16, Nilesh Kalariya17, Aishwarya Sannareddy, MBBS18, Danai Dima, MD19, Jack Khouri, MD20, Joseph P. McGuirk, DO21, Frederick L. Locke, MD22, Rachid C. Baz, MD23, Krina Patel, MD, MSc24 and Melissa Alsina, MD25

https://ash.confex.com/ash/2022/webprogram/Paper163464.html
2019 Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS 1, Jeffrey V. Matous, MD2, Michaela Liedtke, MD3, Surbhi Sidana, MD4, Olalekan O. Oluwole, MBBS5, Meera Mohan, MD, MS6, Jose C. Cruz, MD7, Rajneesh Nath, MD8, Faiz Anwer, MD9, Adriana Rossi, MD, MSc9, Myo Htut, MD10, Shahbaz A. Malik, MD10, Srinivasa Ghatta, PhD11, Myles Dillon, PhD11, Wendy Ying, PhD12, Lynn Navale, MS12, Erin E. Karski, MD12, Arun Balakumaran, MD13 and Shaji K Kumar, MD14

https://ash.confex.com/ash/2022/webprogram/Paper158231.html

3414 Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data

Sara J. Schonfeld, PhD1, Bryan Valcarcel, MD1, Christa L. Meyer, MS2, Ann M Brunson, MS3, Julianne J.P. Cooley, MS4, Renata Abrahao, MD, PhD, MSc5, Ted Wun, MD6, Jeffery Auletta, MD7,8, Lori Muffly, MD, MS9, Theresa H.M. Keegan, PhD9 and Lindsay M. Morton, PhD9

https://ash.confex.com/ash/2022/webprogram/Paper159010.html

3421 Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018

Bryan Valcarcel, MD1, Sara J. Schonfeld, PhD1, Christa L. Meyer, MS2, Ann M Brunson, MS3, Julianne J.P. Cooley, MS4, Renata Abrahao, MD, PhD, MSc5, Ted Wun, MD6, Jeffery Auletta, MD7,8, Lori Muffly, MD, MS9, Theresa H.M. Keegan, PhD9 and Lindsay M. Morton, PhD9

https://ash.confex.com/ash/2022/webprogram/Paper160330.html

2275 Interim Update on the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies
4520 Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California

Naseem S Esteghamat, MD, MS1, Ann M Brunson, MS2*, Ted Wun, MD3, Aaron S Rosenberg, MD1, Julianne J.P. Cooley, MS4, Sara J. Schonfeld, PhD5, Christa L. Meyer, MS6, Bryan Valcarcel, MD7, Renata Abrahao, MD, PhD, MSc8, Jeffery Auletta, MD9, Lindsay M. Morton, PhD10, Lori Muffly, MD10* and Theresa H.M. Keegan, PhD10

https://ash.confex.com/ash/2022/webprogram/Paper159776.html

3621 Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study

Lori Muffly, MD, MS1, Christopher Young, PhD2*, Bin Xie, PhD2, Alana Block, PharmD2, Maelys Touya, PharmD3* and Bhavik J. Pandya, PharmD2*

https://ash.confex.com/ash/2022/webprogram/Paper157964.html

3408 Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Everett H Meyer, MD, PhD1*, M Scott Killian, PhD2, Anna Pavlova, MD, PhD3, Cameron Bader3*, Sean Summers3*, Fernando Teque3*, J Scott McClellan, MD, PhD and Nathaniel B Fernhoff, PhD2*

https://ash.confex.com/ash/2022/webprogram/Paper164468.html

4719 The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease

Nahid Rashid, MD1,2, Mukta Arora, MD3, Paul A. Carpenter, MD4, Amin M Alousi, MD5, Betty K. Hamilton, MD6, Joseph Pidala, MD7, Lynn E. Onstad, ScM8, Corey Cutler, MD, MPH, FRCPC9, Mary E. D. Flowers, MD1, Sally Arai, MD10, Smita Bhatia, MD, MPH10 and Stephanie J. Lee, MD, MPH4

https://ash.confex.com/ash/2022/webprogram/Paper167901.html
4767 Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, MD, PhD1, Moneeza Walji, MD, BSc, MPH2, Samantha Brown, MS2, Sean M. Devlin, PhD2, Esperanza B. Papadopoulos, MD3,4, Ann A Jakubowski, MD PhD3,4, Doris M. Ponce, MD3,7, James W. Young, MD2, Sergio A Giralt, MD10,11, Miguel-Angel Perales, MD6,11, Brian C. Shaffer, MD1,8, Parastoo B. Dahi, MD8,12, Richard J. Lin, MD8,11, Christina Cho, MD8, Roni Tamari, MD8,13, Melody Smith, MD, MS14,15 and Boglarka Gyurkocza, MD5,6

https://ash.confex.com/ash/2022/webprogram/Paper170088.html

3335 A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Miguel-Angel Perales, MD1, Sairah Ahmed, MD2, Saurabh Dahiya, MD3, Peter A. Riedell, MD4, Joseph P. McGuirk, DO5, Olalekan O. Oluwole, MBBS6, Sohail A. Chaudhry, MD7, Zachary Lee, PharmD7, Stanley Dai7, Neha Dixit, PhD7, Christie Fanton, PhD7, Mario Q. Marcondes, MD, PhD7, Jonathan Zalevsky, PhD7, Mary A. Tagliaferri, MD7 and Cameron J. Turtle, MBBS, PhD7

https://ash.confex.com/ash/2022/webprogram/Paper162511.html

2032 Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Arushi Khurana, MBBS1, Megumi Bailey, MSc2, Madiha Iqbal, MD2, Radhika Bansal, MBBS3, Catherine J. Lee, MD4, Bradley Hunter, MD, MPH6, Matthew A. Lunning, DO, FACP7, Samantha Jaglowski, MD, MPH7, Michael D. Jain, MD, PhD8, Saurabh Dahiya, MD9, Veronika Bachanova, MD, PhD8, Umar Farooq, MD11, Sairah Ahmed, MD12, Brian T. Hill, MD, PhD13, Javier L Munoz, MD, MBA14, Krish Patel, MD15, Olalekan O. Oluwole, MBBS16 and Yi Lin, MD, PhD17

https://ash.confex.com/ash/2022/webprogram/Paper170486.html

4287 Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant
ASH SCIENTIFIC WORKSHOP

CAR T-Cells and the Gut Microbiome

Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS
Scientific Workshops
Session: CAR T-cell Toxicities and Associations with Cytokine Profiling and the Gut Microbiome
Friday, December 9, 2022, 3:00 PM-4:00 PM
271-273 (Ernest N. Morial Convention Center)

Melody Smith, MD, MS

https://ash.confex.com/ash/2022/webprogram/Paper171531.html